Quinolines and derivatives
Lomefloxacin Hydrochloride 98.0+%, TCI America™
CAS: 98079-52-8 Molecular Formula: C17H20ClF2N3O3 Molecular Weight (g/mol): 387.812 MDL Number: MFCD00214312 InChI Key: KXEBLAPZMOQCKO-UHFFFAOYSA-N Synonym: 1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic Acid Hydrochloride PubChem CID: 68624 ChEBI: CHEBI:6518 IUPAC Name: 1-ethyl-6,8-difluoro-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid;hydrochloride SMILES: CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O.Cl
Apexbio Technology LLC Nifuroxazide 965-52-6 200mg
Nifuroxazide (CAS 965-52-6) is a small-molecule inhibitor targeting signal transducer and activator of transcription (STAT) signaling pathways It is designed to inhibit activation of STAT1 STAT3 and STAT5 thereby suppressing cytokine-mediated transcriptional activities Nifuroxazide exerts its biological activity primarily through inhibition of STAT phosphorylation and activation In cell-based assays Nifuroxazide demonstrates inhibitory activity with an IC50 value of approximately 3 M against STAT3 phosphorylation and activation in IL-6-stimulated U3A cells Based on these pharmacological properties Nifuroxazide holds research potential in studies of STAT-driven signaling processes and in exploring therapeutic strategies for diseases associated with aberrant cytokine signaling and STAT pathway activation
Medchemexpress LLC Selumetinib | 606143-52-6 | 99.6% | C17H15BrClF4O3 | 200 MG
Selumetinib is a selective, non-ATP-competitive oral MEK1/2 inhibitor with an IC50 of 14 nM for MEK1. It inhibits ERK1/2 phosphorylation and can penetrate the blood-brain barrier. This compound causes a time- and dose-dependent reduction in DNA synthesis and cell viability, inducing growth arrest and apoptosis associated with ERK inactivation.
- Selective, non-ATP-competitive oral MEK1/2 inhibitor
- Inhibits ERK1/2 phosphorylation
- Penetrates the blood-brain barrier
- Induces growth arrest and apoptosis
- Shows anti-proliferative effects
Medchemexpress LLC N-(ethoxycarbonylmethyl)-6-methoxyquinolinium bromide | 162558-52-3 | 99.8% | 200 MG
MQAE is a chloride ion (Cl-) fluorescent probe designed for measuring chloride concentrations. Its fluorescence intensity decreases proportionally as chloride ion levels increase, making it suitable for various detection methods like confocal microscopy and flow cytometry (Ex/Em=350/460 nm). It exhibits high cell permeability and is intended for research use only.
- Suitable for measuring chloride concentrations
- Fluorescence intensity decreases with increasing chloride ions
- High cell permeability
- Compatible with confocal microscopy and flow cytometry
Medchemexpress LLC Pazopanib (GW786034) | 444731-52-6 | MFCD11616589 | 99.9% | 437.52 g/mol | C21H23N7O2S | 200 MG
Pazopanib (GW786034) is a small-molecule, multi-target tyrosine kinase inhibitor provided as a research-grade solid. It potently inhibits VEGFR1, VEGFR2, and VEGFR3 and shows activity against PDGFRβ, c-Kit, FGFR1, and c-Fms, with reported IC50 values in the low nanomolar range; it also inhibits VEGF-induced proliferation and VEGFR-2 phosphorylation in HUVEC cells.
- Multi-target VEGFR/PDGFR tyrosine kinase inhibitor
- Potent enzyme inhibition with IC50s: VEGFR1 10 nM, VEGFR2 30 nM, VEGFR3 47 nM
- Cellular activity: inhibits VEGF-induced proliferation and VEGFR-2 phosphorylation (~8 nM)
- High purity (99.9%) solid suitable for research applications
- Available in research packaging sizes including 200 mg
Apexbio Technology LLC Rocilinostat (ACY-1215) 1316214-52-4 200mg
Rocilinostat (ACY-1215 CAS 1316214-52-4) is a selective inhibitor of histone deacetylase 6 (HDAC6) HDAC6 enzymatically regulates various cellular processes including protein trafficking cell-cycle progression and cytoskeletal organization and its dysregulated activity is implicated in tumor progression and cancer metastasis Rocilinostat potently inhibits HDAC6 (IC50 5 nM) while showing minimal activity against other HDAC isoforms and sirtuins (IC50 1 M) Preclinical studies using multiple myeloma (MM) cell lines and xenograft mouse models demonstrated rocilinostat can enhance acetylation of -tubulin disrupt protein stability pathways and sensitize cancer cells to proteasome inhibitors such as bortezomib and carfilzomib resulting in increased apoptosis and reduction in tumor growth